15 July 2020

Enhancing manufacturing capacity in endemic countries

As part of its activities to develop a pediatric formulation for the treatment of schistosomiasis in preschool-age children, the Pediatric Praziquantel Consortium has recognized the critical need for building local manufacturing and distribution capacity in endemic countries.

Through the collaborative efforts of Consortium partners – Astellas (Japan), Merck (Germany) and Farmanguinhos (Brazil) – knowledge and technologies are being transferred to Contract Manufacturing Organizations in targeted endemic countries. This technology transfer and training will lead to self-sufficiency in terms of product manufacturing, potentially allowing countries to meet the needs of their communities without external support. It will also ensure sustainable access to the pediatric medication once it has been registered and made available.

In addition, as a tangible and valuable contribution of the Consortium’s procurement and access program, these trainings will serve to qualify the local manufacturing sites according to the quality standards and regulations, fostering their reputation and contribution to public health.